These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 21427374)

  • 1. Use of fibrates in the United States and Canada.
    Jackevicius CA; Tu JV; Ross JS; Ko DT; Carreon D; Krumholz HM
    JAMA; 2011 Mar; 305(12):1217-24. PubMed ID: 21427374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician variation in the de-adoption of ineffective statin and fibrate therapy.
    Everhart A; Desai NR; Dowd B; Herrin J; Higuera L; Jeffery MM; Jena AB; Ross JS; Shah ND; Smith LB; Karaca-Mandic P
    Health Serv Res; 2021 Oct; 56(5):919-931. PubMed ID: 33569804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrate use in the United States and Canada.
    Lim LS; Wong TY
    JAMA; 2011 Jul; 306(2):157-8; author reply 158-9. PubMed ID: 21750289
    [No Abstract]   [Full Text] [Related]  

  • 4. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2010 Jun; 9():24. PubMed ID: 20550659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrate use in the United States and Canada.
    Tenenbaum A; Fisman EZ
    JAMA; 2011 Jul; 306(2):157; author reply 158-9. PubMed ID: 21750290
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes.
    Elam MB; Ginsberg HN; Lovato LC; Corson M; Largay J; Leiter LA; Lopez C; O'Connor PJ; Sweeney ME; Weiss D; Friedewald WT; Buse JB; Gerstein HC; Probstfield J; Grimm R; Ismail-Beigi F; Goff DC; Fleg JL; Rosenberg Y; Byington RP;
    JAMA Cardiol; 2017 Apr; 2(4):370-380. PubMed ID: 28030716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.
    Enger C; Gately R; Ming EE; Niemcryk SJ; Williams L; McAfee AT
    Am J Cardiol; 2010 Dec; 106(11):1594-601. PubMed ID: 21094360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do persons with diabetes benefit from combination statin and fibrate therapy?
    Rosenblit PD
    Curr Cardiol Rep; 2012 Feb; 14(1):112-24. PubMed ID: 22213157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Fibrates: their prescription must be restricted].
    Béliard-Lasserre S
    Rev Prat; 2015 Dec; 65(10):1243-4. PubMed ID: 26979011
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.
    Hamilton-Craig I; Kostner KM; Woodhouse S; Colquhoun D
    Int J Evid Based Healthc; 2012 Sep; 10(3):181-90. PubMed ID: 22925614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
    Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
    Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
    Alford JC; Saseen JJ; Allen RR; Nair KV
    Pharmacotherapy; 2012 Jul; 32(7):623-30. PubMed ID: 22570173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertriglyceridemia Therapy: Past, Present and Future Perspectives.
    Canfora I; Pierno S
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrate use in diabetes: new concepts.
    Bloomgarden ZT; Drexler A
    J Diabetes; 2011 Mar; 3(1):1-2. PubMed ID: 21159144
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials.
    Sahebkar A; Simental-Mendía LE; Pirro M; Montecucco F; Carbone F; Banach M; Barreto GE; Butler AE
    Ann Med; 2018 Sep; 50(6):485-493. PubMed ID: 29957074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.